Develops ivonescimab, an investigational cancer medicine, for patients with lung and colorectal cancers.
10-K for FY2025, filed Feb 23, 2026Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and…View ↗
The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine…View ↗
The Company is developing ivonescimab in non-small cell lung cancer (“NSCLC”) and colorectal cancer (“CRC”), specifically conducting Phase…View ↗
Beyond NSCLC, we are currently conducting the Phase III study for patients with first line metastatic unresectable CRC, HARMONi-GI3. For…View ↗
The company is developing ivonescimab for patients with lung and colorectal cancers; its current work is focused on clinical trials rather than commercial sales.
10-K for FY2025, filed Feb 23, 2026
10-Q for Q3 FY2026, filed Nov 4, 2026
−$208.4MView ↗
8-K, filed Sep 29, 2026
On September 28, 2026, Summit Therapeutics Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”)…View ↗
8-K, filed Aug 5, 2026
On August 5, 2026, Summit Therapeutics Inc. issued a press release announcing the expansion of its global registration-enabling clinical…View ↗
Focus shifted to oncology
The older report described a pipeline that included antibiotics for drug-resistant infections and ridinilazole for C. difficile, alongside the new ivonescimab license. The latest report centers the business on developing ivonescimab for cancer.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 23, 2026We are a biopharmaceutical company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and…View ↗
The entry into the License Agreement represents a significant change in the Company’s strategy. All prior development and marketing…View ↗
Our other product candidate, SMT-738, has been in development for combating multidrug resistant infections, specifically…View ↗
Summit Therapeutics Inc. (“we”, “Summit” or the “Company”) is a biopharmaceutical company focused on the discovery, development, and…View ↗
The Company’s current lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine…View ↗
The Company is developing ivonescimab in non-small cell lung cancer (“NSCLC”) and colorectal cancer (“CRC”), specifically conducting Phase…View ↗
Competes with BioNTech, Bristol Myers Squibb, Pfizer, Merck &, AbbVie, AstraZeneca, Daiichi Sankyo, and Johnson & Johnson
10-K for FY2025, filed Feb 23, 2026There are no known PD-1-based bispecific antibodies currently approved by the FDA, the European Medicines Agency (“EMA”), or Japan’s…View ↗
Loading...